Metabolomic Profiling in Ischemic and Non-Ischemic Cardiomyopathy Patients With Ventricular Arrhythmias

NCT07507539 | Completed

• 1 other identifier: IU-CERRAHPASA-METABOLOMICS-01
• Study Type: observational
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

This single-center prospective observational study aims to evaluate differences in metabolomic pathways between patients with ischemic and non-ischemic cardiomyopathy with reduced left ventricular ejection fraction and documented ventricular tachycardia. Patients followed at Istanbul University-Cerrahpasa Cardiology Institute Hospital will be included if they meet predefined eligibility criteria. Participants will be categorized into two cohorts according to the etiology of cardiomyopathy: ischemic and non-ischemic. Biospecimens will be collected for metabolomic analyses to identify alterations in metabolic pathways and individual metabolites. The study also aims to explore associations between metabolomic profiles and clinical characteristics, including arrhythmia burden and cardiac function parameters. The findings may provide insights into the underlying pathophysiological mechanisms of ventricular arrhythmias in heart failure and contribute to improved risk stratification and personalized management strategies.

Conditions

Heart Failure With Reduced Ejection Fraction (HFrEF); Ventricular Tachycardia (VT); Ischemic Cardiomyopathy; Non-ischemic Cardiomyopathy

Keywords

Metabolomics; Arrhythmia; Ventricular Tachycardia; Heart Failure; HFrEF; Ischemic Cardiomyopathy; Non-ischemic Cardiomyopathy; Metabolic Pathways; Biomarkers; Risk Stratification

Outcome Measures

Primary Outcomes (1)

• Differences in metabolomic pathways between ischemic and non-ischemic cardiomyopathy

  Comparison of metabolomic pathway profiles derived from biospecimen analyses between patients with ischemic and non-ischemic cardiomyopathy with reduced ejection fraction and documented ventricular tachycardia.

  Baseline

Secondary Outcomes (2)

• Differences in individual metabolite levels between groups

  Baseline

• Association between metabolomic profiles and clinical parameters

  Baseline

Study Arms (2)

Ischemic cardiomyopathy

Patients with ischemic cardiomyopathy, left ventricular ejection fraction below 40%, and documented ventricular tachycardia.

Non-ischemic cardiomyopathy

Patients with non-ischemic cardiomyopathy, left ventricular ejection fraction below 40%, and documented ventricular tachycardia.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adult patients (≥18 years) with ischemic or non-ischemic cardiomyopathy and reduced left ventricular ejection fraction (\<40%) who have documented ventricular tachycardia and are followed at Istanbul University-Cerrahpasa Cardiology Institute Hospital.

You may qualify if:

• Age ≥18 years Diagnosis of ischemic or non-ischemic cardiomyopathy Left ventricular ejection fraction \<40% Documented ventricular tachycardia detected by Holter monitoring, implantable cardioverter-defibrillator (ICD), pacemaker, or other implantable rhythm monitoring devices Availability of metabolomic sample collection Ability and willingness to provide informed consent

You may not qualify if:

• History of cardiotoxic chemotherapy or radiotherapy Cirrhosis or advanced hepatic failure Active malignancy Acute decompensated heart failure at presentation Active infection or acute inflammatory disease End-stage renal disease requiring dialysis Absence of Holter monitoring or implantable rhythm monitoring data No documented ventricular tachycardia despite rhythm monitoring Inability to provide informed consent

Sponsors & Collaborators

• Muhammed Heja Geçit: lead

Study Sites (1)

Istanbul University-Cerrahpasa Cardiology Institute

Istanbul, 34098, Turkey (Türkiye)

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

Peripheral blood samples will be collected from all participants and processed to obtain serum and plasma for metabolomic analyses. Samples will be stored under appropriate conditions and used to evaluate metabolic pathways and individual metabolite profiles.

MeSH Terms

Conditions

Tachycardia, Ventricular; Arrhythmias, Cardiac; Heart Failure

Condition Hierarchy (Ancestors)

Tachycardia; Heart Diseases; Cardiovascular Diseases; Cardiac Conduction System Disease; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 1 Month
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Cardiology Resident

Study Record Dates

• First Submitted: March 27, 2026
• First Posted: April 2, 2026
• Study Start: March 2, 2025
• Primary Completion: March 25, 2026
• Study Completion: March 25, 2026
• Last Updated: April 2, 2026

Record last verified: 2026-03

Locations

TU (1)